Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Broglé KC. Whiteside GT, et al. J Pharmacol Exp Ther. 2004 Aug;310(2):793-9. doi: 10.1124/jpet.103.063560. Epub 2004 Mar 30. J Pharmacol Exp Ther. 2004. PMID: 15054116
Pharmacological characterisation of a rat model of incisional pain.
Whiteside GT, Harrison J, Boulet J, Mark L, Pearson M, Gottshall S, Walker K. Whiteside GT, et al. Br J Pharmacol. 2004 Jan;141(1):85-91. doi: 10.1038/sj.bjp.0705568. Epub 2003 Nov 3. Br J Pharmacol. 2004. PMID: 14597606 Free PMC article.
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT. Valenzano KJ, et al. Among authors: whiteside gt. Neuropharmacology. 2005 Apr;48(5):658-72. doi: 10.1016/j.neuropharm.2004.12.008. Neuropharmacology. 2005. PMID: 15814101
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.
Ilyin VI, Pomonis JD, Whiteside GT, Harrison JE, Pearson MS, Mark L, Turchin PI, Gottshall S, Carter RB, Nguyen P, Hogenkamp DJ, Olanrewaju S, Benjamin E, Woodward RM. Ilyin VI, et al. Among authors: whiteside gt. J Pharmacol Exp Ther. 2006 Sep;318(3):1083-93. doi: 10.1124/jpet.106.104737. Epub 2006 May 25. J Pharmacol Exp Ther. 2006. PMID: 16728593
Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain.
Sullivan NR, Leventhal L, Harrison J, Smith VA, Cummons TA, Spangler TB, Sun SC, Lu P, Uveges AJ, Strassle BW, Piesla MJ, Ramdass R, Barry A, Schantz J, Adams W, Whiteside GT, Adedoyin A, Jones PG. Sullivan NR, et al. Among authors: whiteside gt. J Pharmacol Exp Ther. 2007 Sep;322(3):1294-304. doi: 10.1124/jpet.106.118604. Epub 2007 Jun 22. J Pharmacol Exp Ther. 2007. PMID: 17586724
54 results